Addus HomeCare (ADUS) Could Be 12% Below Fair Value As Q2 Results Steady Nerves
Addus HomeCare (ADUS) is back on investors radar after releasing its second quarter 2026 results. The company met revenue expectations, slightly exceeded non GAAP profit forecasts, and kept operating margins stable.
See our latest analysis for Addus HomeCare.
The Q2 report appears to be the main driver of recent trading in Addus HomeCare, with the stock showing a 30 day share price return of 11.05% and a 90 day share price return of 20.85%. Over a longer horizon, total shareholder return sits at 0.19% over one year and 29.44% over five years. This points to longer term value creation even as near term momentum has recently picked up.
If the latest move in Addus HomeCare has you looking across healthcare, this could be a useful moment to review 40 healthcare AI stocks as another potential source of stock ideas.
Bulls see Addus HomeCare’s steady earnings and margin profile as support for the recent rerating. Bears question whether the latest run already reflects that strength. The valuation numbers indicate which side currently has more support.
Most Popular Narrative: 12% Undervalued
The most followed narrative currently places fair value for Addus HomeCare at $132.69 per share, compared with the latest close at $116.79. This frames the recent Q2 move in a wider context.
Recent and upcoming state level reimbursement rate increases in major markets (Illinois and Texas) are expected to add over $35 million in annualized revenue at stable 20%+ margins, directly supporting top line growth and net margin expansion.
Read the complete narrative. Read the complete narrative.
Want to see what underpins that valuation gap for Addus HomeCare? Analysts model steady revenue expansion, firmer margins, and a higher future earnings base, then discount those projections using a defined required return.
Result: Fair Value of $132.69 (UNDERVALUED)
Have a read of the narrative in full and understand what's behind the forecasts.
However, Addus HomeCare’s heavy reliance on Medicaid and Medicare reimbursement, along with potential Medicare payment cuts to home health, could challenge that undervalued narrative if conditions tighten.
Find out about the key risks to this Addus HomeCare narrative.
Next Steps
With the market focus already sharpened on Addus HomeCare, this is a good moment to review the numbers yourself and test how the story fits your own risk tolerance. To see what other investors view as the main positives around the stock, take a closer look at the 4 key rewards.
Looking for more investment ideas beyond Addus HomeCare?
If you are serious about building a stronger portfolio, now is the time to scan for other opportunities that fit your goals instead of waiting for the next headline.
- Target potential mispricings by reviewing a focused list of 52 high quality undervalued stocks that combine quality fundamentals with more attractive entry points.
- Prioritise resilience by checking companies in the 80 resilient stocks with low risk scores that score well on financial health and business stability.
- Spot lesser known opportunities early by running through the screener containing 18 high quality undiscovered gems that pair solid fundamentals with lower market attention.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com